Botulinum Toxin Type B (MyoBloc) in the Management of Hyperkinetic Facial Lines

Abstract

OBJECTIVE: Our goal was to evaluate the safety and efficacy of botulinum toxin type B (BTX-B) in the management of hyperfunctional facial lines.

STUDY DESIGN AND SETTING: Twenty-four patients from an academic faculty practice were treated with 400 to 800 units BTX-B in the corrugator, orbicularis oculi, or frontalis. Patients were evaluated with the Wrinkle Improvement Score (WIS) and Rated Numeric Kinetic Line Scale (RNKLS) and questioned about side effects and pain. Evaluations were made at 1, 2, 4, 8, and 12 weeks.

RESULTS: Onset of effect was within 72 hours. WIS and RNKLS for all sites were statistically better after treatment, with the effect lasting 8 weeks. In general, patients noted a moderate improvement (grade 2) on WIS and a 2-point improvement on RNKLS. Injection was more painful than that of BTX-A. There were no complications.

CONCLUSION: BTX-B is a safe and effective technique to eliminate wrinkles. Further studies are needed to elucidate dosage and duration.

SIGNIFICANCE: BTX-B is stable for prolonged periods of time, requires no preparation before use, and is antigenetically distinct from BTX-A.

Get full access to this article

View all access options for this article.

References

Blitzer

Sulica

. Botulinum toxin: Basic science and clinical uses in otolaryngology. Laryngoscope 2001; 111: 218–26.

Brin

. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997;(suppl 6): 146–63.

Blitzer

Brin

Keen

, et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993;119:1018–23.

Keen

Blitzer

Aviv

, et al. Botulinum toxin A for hyperkinetic facial lines: Results of a double-blind, place-bo-controlled study. Plast Reconstr Surg 1994;94:94–9.

Blitzer

Binder

Aviv

, et al. The management of hyperfunctional facial lines with botulinum toxin. Arch Otolaryngol Head Neck Surg 1997;123:289–392.

Guyuron

Huddleston

. Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg 1994;93:913–8.

Ahn

Catten

Maas

. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg 2000; 105: 1129–35.

Bikhazi

Maas

. Refinement in the rehabilitation of the paralyzed face using botulinum toxin. Otolaryngol Head Neck Surg 1997;117:303–7.

Tsui

Hayward

Mak

, et al. Botulinum toxin type B in the treatment of cervical dystonias: A pilot study. Neurology 1995;45:2109–10.

10.

Lew

Adornato

Duane

, et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 45: 701–7.

11.

Brashear

Lew

Dykstra

, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439–46.

12.

Lew

Brashear

Factor

. The safety and efficacy of botulinum toxin type b in the treatment of patients with cervical dystonia: Summary of three controlled clinical trials. Neurology 2000; 55: S29–35.

13.

Setler

. The biochemistry of botulinum toxin type B. Neurology 2000; 55(suppl 5):22–8.

14.

Callaway

Arezzo

Grethlein

. Botulinum toxin type B: An overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 2001; 20:127–36.

15.

Sloop

Cole

Escutin

. Human response to botulinum toxin injection: Type B compared with type A. Neurology 1997;49:189–94.

16.

Tucker

Frey

, et al. Measuring injection-site pain associated with vaccine administration in adults: A randomised, double-blind, placebo-controlled clinical trial. J Epidemiol Biostat 2000;5:359–66.

17.

Fagian

. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: Adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999; 103: 701–13.

18.

Benedetto

. The cosmetic uses of botulinum toxin type A. Int J Dermatol 1999;38:641–55.